Truist analyst Richard Newitter raised the firm’s price target on Integra LifeSciences to $48 from $44 and keeps a Hold rating on the shares. Intra-quarter data points, including the firm’s Q2 hospital survey, increase confidence that procedure momentum will extend beyond Q2 into 2H23 with MedTech companies poised to deliver healthy beat and raises, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences upgraded to Buy from Hold at Jefferies
- Integra LifeSciences to Host Second Quarter 2023 Financial Results Conference Call on July 27, 2023
- Integra completes enrollment inDuraSorb U.S. IDE study for breast reconstruction
- Integra LifeSciences Announces Complete Enrollment in DuraSorb® Monofilament Mesh U.S. IDE Study
- Integra LifeSciences price target lowered to $44 from $55 at Piper Sandler